Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells $63,190.26 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 2,061 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $30.66, for a total value of $63,190.26. Following the sale, the insider directly owned 136,216 shares in the company, valued at approximately $4,176,382.56. This represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mark Hopman also recently made the following trade(s):

• On Wednesday, March 4th, Mark Hopman sold 353 shares of Beta Bionics stock. The stock was sold at an average price of $11.57, for a total transaction of $4,084.21.
• On Monday, March 2nd, Mark Hopman sold 834 shares of Beta Bionics stock. The shares were sold at an average price of $12.36, for a total transaction of $10,308.24.

Beta Bionics Price Performance

BBNX stock opened at $10.63 on Thursday. The firm has a market cap of $471.76 million, a price-to-earnings ratio of -5.45 and a beta of 5.60. Beta Bionics, Inc. has a 1-year low of $8.89 and a 1-year high of $32.71. The firm has a fifty day moving average price of $14.31 and a two-hundred day moving average price of $21.88.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The company had revenue of $32.12 million for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GPS Wealth Strategies Group LLC increased its stake in shares of Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. Summit Securities Group LLC acquired a new position in shares of Beta Bionics during the fourth quarter worth approximately $52,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after buying an additional 1,594 shares in the last quarter. Finally, Strs Ohio bought a new position in Beta Bionics in the 1st quarter worth approximately $29,000.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BBNX. Bank of America downgraded Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. Lake Street Capital set a $20.00 price target on Beta Bionics in a research report on Wednesday, February 18th. The Goldman Sachs Group reissued a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a report on Thursday, January 15th. Truist Financial reduced their price objective on Beta Bionics from $37.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, TD Cowen initiated coverage on Beta Bionics in a research note on Monday, January 26th. They set a “hold” rating and a $17.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.